India-based drug manufacturer Cadila Healthcare has announced that it is planning to file a Biologics License Application (BLA) for its biosimilar pegfilgrastim with the FDA by the end of 2019. To date, no developer has been successful in gaining regulatory approval in the United States or European Union for a biosimilar of the reference pegfilgrastim.
India-based drug manufacturer Cadila Healthcare has announced that it is planning to file a Biologics License Application (BLA) for its biosimilar pegfilgrastim with the FDA by the end of 2019. To date, no developer has been successful in gaining regulatory approval in the United States or European Union for biosimilars of the reference pegfilgrastim.
Cadila’s proposed biosimilar references Amgen’s innovator product, Neulasta, which brought in about $4.5 billion in global sales last year. One of the challenges of developing a biosimilar pegfilgrastim is the presence of polyethylene glycol (PEG) molecule, which is bonded to filgrastim and slows the rate at which the drug is metabolized. Cadila’s proposed biosimilar is currently undergoing a phase 1 clinical trial where it is being tested in healthy volunteers for safety.
“We are discussing to do more [biosimilars for regulated markets],” said Sharvil Patel, managing director of Cadila Healthcare, as reported by Indian media. Meanwhile, Patel said, the company is planning to “aggressively push its biosimilars in semi-regulated emerging markets to boost revenues.” Cadila expects its biosimilar sales to have the potential to reach $500 million in the next 5 to 7 years, a large increase from the $45 million it currently produces.
Cadila is familiar with the development process of biosimilars, as it has already launched 8 such products in India. However, the FDA biosimilar regulatory pathway is among the most stringent in the world, and differs significantly from that in India.
Fellow Indian drug developer Biocon, together with partner Mylan, also filed a BLA for a biosimilar pegfilgrastim with the FDA, however, the application received a complete response letter (CRL) in October relating to “data from facility requalification activities” after recent adjustments to its manufacturing plant. Biocon said that the CRL did not raise question concerning the drug’s biosimilarity, pharmacokinetic or pharmacodynamic data, clinical data, or immunogenicity. Reportedly, the manufacturers are hopeful to re-file later this year.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.